A 40-year partnership of faith, family, and fellowship that grew from Roche Laboratories s to careers in healthcare and ...

The results of the clinical trial mark a setback for the Swiss pharmaceutical company, which saw in the drug, giredestrant, a ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

Measured in blood samples, the biomarker p-tau217 was strongly linked to future dementia risk across decades of follow-up in a large, diverse cohort of U.S. women ...

An already-approved IV drug significantly reduces the symptoms of lupus, a new clinical trial showed. More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant ...

He is the lead principal investigator of the ALLEGORY study and the lead author and he has also presented the results last Friday at SLEuro. Today, Dr. Richard Furie will take us again through the ...

Shares in Roche fell as much as 8% in early morning trade Monday, amid broad-based losses across European stocks due to the conflict in the Middle East and surging oil prices, before paring back the ...

But "no meaningful differences" were observed in overall healthcare-related financial stra ...

A new study from researchers led by Johns Hopkins Medicine reports substantial new evidence that elevated blood biomarkers of subclinical heart injury or stress — heart muscle damage without symptoms ...

Investors who want to capitalize on the growing weight loss market might be tempted to turn to the current leaders in the ...

Zealand and Roche are jointly developing the drug petrelintide which in a mid-stage study led to a worse-than-expected 10.7% ...

An amylin-targeting medicine at the center of the companies’ multibillion-dollar alliance spurred less weight loss than ...